Features and properties of durvalumab

Alternative names	Anti-PD-L1 monoclonal antibody; Anti-PD-LI mAb; anti-programmed cell death 1 ligand 1 monoclonal antibody; Imfinzi; MEDI-4736
Class	Antineoplastics; monoclonal antibodies
Mechanism of action	CD274 antigen inhibitors
Route of administration	Intravenous
Pharmacodynamics	Binds to PD-L1 with high affinity and selectivity, blocking its interaction with PD-1 and CD80 receptors; induces T-cell activation and proliferation; inhibits tumour growth in xenograft models.
Pharmacokinetics	Dose-proportional pharmacokinetics at ≥3 mg/kg; mean terminal half-life 17 days;
Most frequent adverse events	Fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral oedema and urinary tract infection
ATC codes
WHO ATC code	B06A (other hematological agents); L01X-C28 (durvalumab)
EphMRA ATC code	B6C (other haematological agents); L1G (monoclonal antibody antineoplastics); L1X9 (all other antineoplastics)
Chemical name	Immunoglobulin G1-kappa, anti-(human programmed cell death 1 ligand 1 (B7 homolog 1, CD274)); human monoclonal antibody; γ1 heavy chain (1-451) [human VH (IGHV3-7*01 (99%)–IGHJ4*01) [8.8.14] (1–121)–IGHG1*03 (CH1 (122–219), hinge (220–234), CH2 L4 > F(238), L5 > E(239), P101 > S(335) (235-344), CH3 (345–451)) (122–451)] (224–215′)-disulfide with κ light chain (1′–215′) [human V-KAPPA (IGKV3-20*01 (97%)–IGKJ1*01) [7.3.9] (1′–108′)–IGKC*01(109′–215′)] dimer (230–230″:233–233″)-bisdisulfide